Logo image of ANIP

ANI PHARMACEUTICALS INC (ANIP) Stock Fundamental Analysis

NASDAQ:ANIP - Nasdaq - US00182C1036 - Common Stock - Currency: USD

68.815  +2.94 (+4.47%)

Fundamental Rating

5

Overall ANIP gets a fundamental rating of 5 out of 10. We evaluated ANIP against 193 industry peers in the Pharmaceuticals industry. ANIP has an average financial health and profitability rating. An interesting combination arises when we look at growth and value: ANIP is growing strongly while it also seems undervalued.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

In the past year ANIP was profitable.
ANIP had a positive operating cash flow in the past year.
In the past 5 years ANIP reported 4 times negative net income.
ANIP had a positive operating cash flow in 4 of the past 5 years.
ANIP Yearly Net Income VS EBIT VS OCF VS FCFANIP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

1.2 Ratios

ANIP has a Return On Assets of -0.50%. This is in the better half of the industry: ANIP outperforms 79.79% of its industry peers.
ANIP's Return On Equity of -1.45% is amongst the best of the industry. ANIP outperforms 81.35% of its industry peers.
Looking at the Return On Invested Capital, with a value of 2.10%, ANIP is in the better half of the industry, outperforming 78.76% of the companies in the same industry.
Industry RankSector Rank
ROA -0.5%
ROE -1.45%
ROIC 2.1%
ROA(3y)-2.12%
ROA(5y)-3.36%
ROE(3y)-5.31%
ROE(5y)-7.87%
ROIC(3y)N/A
ROIC(5y)N/A
ANIP Yearly ROA, ROE, ROICANIP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5 -5 10 -10

1.3 Margins

The Operating Margin of ANIP (3.58%) is better than 79.79% of its industry peers.
ANIP's Operating Margin has declined in the last couple of years.
ANIP has a better Gross Margin (60.17%) than 68.39% of its industry peers.
In the last couple of years the Gross Margin of ANIP has declined.
Industry RankSector Rank
OM 3.58%
PM (TTM) N/A
GM 60.17%
OM growth 3YN/A
OM growth 5Y-47.18%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.51%
GM growth 5Y-3.12%
ANIP Yearly Profit, Operating, Gross MarginsANIP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60 80

More info and screens

4

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so ANIP is destroying value.
Compared to 1 year ago, ANIP has more shares outstanding
The number of shares outstanding for ANIP has been increased compared to 5 years ago.
The debt/assets ratio for ANIP is higher compared to a year ago.
ANIP Yearly Shares OutstandingANIP Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
ANIP Yearly Total Debt VS Total AssetsANIP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

ANIP has an Altman-Z score of 1.93. This is not the best score and indicates that ANIP is in the grey zone with still only limited risk for bankruptcy at the moment.
The Altman-Z score of ANIP (1.93) is better than 65.28% of its industry peers.
The Debt to FCF ratio of ANIP is 9.35, which is on the high side as it means it would take ANIP, 9.35 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 9.35, ANIP belongs to the top of the industry, outperforming 80.83% of the companies in the same industry.
ANIP has a Debt/Equity ratio of 1.38. This is a high value indicating a heavy dependency on external financing.
ANIP's Debt to Equity ratio of 1.38 is on the low side compared to the rest of the industry. ANIP is outperformed by 74.61% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.38
Debt/FCF 9.35
Altman-Z 1.93
ROIC/WACC0.23
WACC9.09%
ANIP Yearly LT Debt VS Equity VS FCFANIP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

A Current Ratio of 2.66 indicates that ANIP has no problem at all paying its short term obligations.
ANIP has a Current ratio (2.66) which is comparable to the rest of the industry.
ANIP has a Quick Ratio of 1.98. This is a normal value and indicates that ANIP is financially healthy and should not expect problems in meeting its short term obligations.
ANIP has a Quick ratio (1.98) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 2.66
Quick Ratio 1.98
ANIP Yearly Current Assets VS Current LiabilitesANIP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

8

3. Growth

3.1 Past

ANIP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 19.54%, which is quite good.
Measured over the past 5 years, ANIP shows a small growth in Earnings Per Share. The EPS has been growing by 0.59% on average per year.
Looking at the last year, ANIP shows a very strong growth in Revenue. The Revenue has grown by 56.85%.
The Revenue has been growing by 24.37% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)19.54%
EPS 3Y16.84%
EPS 5Y0.59%
EPS Q2Q%40.5%
Revenue 1Y (TTM)56.85%
Revenue growth 3Y41.66%
Revenue growth 5Y24.37%
Sales Q2Q%43.43%

3.2 Future

Based on estimates for the next years, ANIP will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.58% on average per year.
Based on estimates for the next years, ANIP will show a quite strong growth in Revenue. The Revenue will grow by 10.09% on average per year.
EPS Next Y27.95%
EPS Next 2Y17.81%
EPS Next 3Y17.22%
EPS Next 5Y12.58%
Revenue Next Year32.08%
Revenue Next 2Y19.09%
Revenue Next 3Y14.88%
Revenue Next 5Y10.09%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
ANIP Yearly Revenue VS EstimatesANIP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M 1B
ANIP Yearly EPS VS EstimatesANIP Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 2 4 6 8 10

More info and screens

8

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 12.09, which indicates a correct valuation of ANIP.
Compared to the rest of the industry, the Price/Earnings ratio of ANIP indicates a rather cheap valuation: ANIP is cheaper than 88.08% of the companies listed in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 27.03, ANIP is valued rather cheaply.
Based on the Price/Forward Earnings ratio of 9.53, the valuation of ANIP can be described as reasonable.
Compared to the rest of the industry, the Price/Forward Earnings ratio of ANIP indicates a rather cheap valuation: ANIP is cheaper than 84.46% of the companies listed in the same industry.
ANIP is valuated cheaply when we compare the Price/Forward Earnings ratio to 36.28, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 12.09
Fwd PE 9.53
ANIP Price Earnings VS Forward Price EarningsANIP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, ANIP is valued cheaper than 80.31% of the companies in the same industry.
ANIP's Price/Free Cash Flow ratio is rather cheap when compared to the industry. ANIP is cheaper than 82.38% of the companies in the same industry.
Industry RankSector Rank
P/FCF 22.37
EV/EBITDA 17.99
ANIP Per share dataANIP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30

4.3 Compensation for Growth

ANIP's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
ANIP's earnings are expected to grow with 17.22% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.43
PEG (5Y)20.6
EPS Next 2Y17.81%
EPS Next 3Y17.22%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ANIP!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ANI PHARMACEUTICALS INC

NASDAQ:ANIP (8/6/2025, 2:14:39 PM)

68.815

+2.94 (+4.47%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-09 2025-05-09/bmo
Earnings (Next)08-06 2025-08-06/bmo
Inst Owners95.9%
Inst Owner Change-1.55%
Ins Owners7.84%
Ins Owner Change8.18%
Market Cap1.49B
Analysts84.29
Price Target82.47 (19.84%)
Short Float %11.8%
Short Ratio6.9
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0.08
Dividend Growth(5Y)N/A
DP-25.25%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)15.96%
Min EPS beat(2)11.36%
Max EPS beat(2)20.55%
EPS beat(4)4
Avg EPS beat(4)14.54%
Min EPS beat(4)5.26%
Max EPS beat(4)20.97%
EPS beat(8)8
Avg EPS beat(8)28.1%
EPS beat(12)11
Avg EPS beat(12)36.05%
EPS beat(16)12
Avg EPS beat(16)13.46%
Revenue beat(2)2
Avg Revenue beat(2)6.75%
Min Revenue beat(2)6.54%
Max Revenue beat(2)6.96%
Revenue beat(4)4
Avg Revenue beat(4)4.78%
Min Revenue beat(4)0.74%
Max Revenue beat(4)6.96%
Revenue beat(8)8
Avg Revenue beat(8)7.86%
Revenue beat(12)12
Avg Revenue beat(12)8.42%
Revenue beat(16)14
Avg Revenue beat(16)6.64%
PT rev (1m)-1.74%
PT rev (3m)-0.7%
EPS NQ rev (1m)2.26%
EPS NQ rev (3m)-7.28%
EPS NY rev (1m)0%
EPS NY rev (3m)3.19%
Revenue NQ rev (1m)1.33%
Revenue NQ rev (3m)0.97%
Revenue NY rev (1m)0.67%
Revenue NY rev (3m)2.91%
Valuation
Industry RankSector Rank
PE 12.09
Fwd PE 9.53
P/S 1.84
P/FCF 22.37
P/OCF 18.45
P/B 3.36
P/tB N/A
EV/EBITDA 17.99
EPS(TTM)5.69
EY8.27%
EPS(NY)7.22
Fwd EY10.49%
FCF(TTM)3.08
FCFY4.47%
OCF(TTM)3.73
OCFY5.42%
SpS37.48
BVpS20.48
TBVpS-7.19
PEG (NY)0.43
PEG (5Y)20.6
Profitability
Industry RankSector Rank
ROA -0.5%
ROE -1.45%
ROCE 2.66%
ROIC 2.1%
ROICexc 2.45%
ROICexgc 6.82%
OM 3.58%
PM (TTM) N/A
GM 60.17%
FCFM 8.21%
ROA(3y)-2.12%
ROA(5y)-3.36%
ROE(3y)-5.31%
ROE(5y)-7.87%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5Y-44.22%
ROICexc growth 3YN/A
ROICexc growth 5Y-46.62%
OM growth 3YN/A
OM growth 5Y-47.18%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.51%
GM growth 5Y-3.12%
F-Score4
Asset Turnover0.63
Health
Industry RankSector Rank
Debt/Equity 1.38
Debt/FCF 9.35
Debt/EBITDA 5.83
Cap/Depr 18.61%
Cap/Sales 1.74%
Interest Coverage 1.15
Cash Conversion 76.92%
Profit Quality N/A
Current Ratio 2.66
Quick Ratio 1.98
Altman-Z 1.93
F-Score4
WACC9.09%
ROIC/WACC0.23
Cap/Depr(3y)17.9%
Cap/Depr(5y)14.57%
Cap/Sales(3y)2.42%
Cap/Sales(5y)2.28%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)19.54%
EPS 3Y16.84%
EPS 5Y0.59%
EPS Q2Q%40.5%
EPS Next Y27.95%
EPS Next 2Y17.81%
EPS Next 3Y17.22%
EPS Next 5Y12.58%
Revenue 1Y (TTM)56.85%
Revenue growth 3Y41.66%
Revenue growth 5Y24.37%
Sales Q2Q%43.43%
Revenue Next Year32.08%
Revenue Next 2Y19.09%
Revenue Next 3Y14.88%
Revenue Next 5Y10.09%
EBIT growth 1Y-44.16%
EBIT growth 3YN/A
EBIT growth 5Y-34.31%
EBIT Next Year33.94%
EBIT Next 3Y19.79%
EBIT Next 5Y14.11%
FCF growth 1Y55608.3%
FCF growth 3Y297.63%
FCF growth 5Y4.15%
OCF growth 1Y781.43%
OCF growth 3Y168.16%
OCF growth 5Y7.01%